Previous 10 | Next 10 |
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 22 nd Annua...
HELP Study results, evaluating levosimendan in patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF), will be presented during a Late-Breaking Clinical Trial session during the HFSA Annual Scientific Meeting Tenax Therapeutics, Inc. (N...
Tenax Therapeutics (NASDAQ: TENX ) has filed a prospectus for the resale of up to 14,958,874 shares of common stock. More news on: Tenax Therapeutics, Inc., Healthcare stocks news, , Read more ...
Tenax Therapeutics (NASDAQ: TENX ) : Q2 GAAP EPS of -$0.23 misses by $0.09 . More news on: Tenax Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the second quarter 2020 and provided a business update. “The recently compl...
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the expansion of its Board of Directors with...
RumbleON (NASDAQ: RMBL ) +117% on pilot program with CarGurus. More news on: RumbleON, Inc., Verona Pharma plc, Applied DNA Sciences, Inc., Stocks on the move, , Read more ...
Tenax Therapeutics (NASDAQ: TENX ) inks agreement with institutional investor for the issuance and sale of 2,523,611 common shares at a purchase price of $1.0278/share and pre-funded warrants to purchase up to 652,313 shares of common stock, at $1.0277/per warrant, in a registere...
Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced ...
Evofem Biosciences (NASDAQ: EVFM ) -26% after pricing equity offering. More news on: Evofem Biosciences, Inc., Cellectar Biosciences, Inc., Reinsurance Group of America, Incorporated, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...